With Its “Impressive” Blood Cancer Treatment, This Small Biotech Is Rivaling Gilead And Novartis

With what are being called “impressive” results for its blood cancer treatment, the small biotech featured in today’s article is rivaling first-in-class treatments from the likes of Gilead Sciences and Novartis. For more on this biotech, its donor cell-derived cancer treatment, and the bullish case for the stock, CLICK HERE.